Expression of the Metastasis Suppressor KAI1 in Uveal Melanoma

Introduction. Uveal melanoma (UM) is an intraocular tumor that leads to metastatic disease in approximately 50% of afflicted patients. There is no efficacious treatment for metastatic disease in this cancer. Identification of markers that can offer prognostic and therapeutic value is a major focus i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Ophthalmology 2013-01, Vol.2013 (2013), p.419-422
Main Authors: Maloney, Shawn C., Fernandes, Bruno F., Penteado, Rafaella Cleto, Antecka, Emilia, Bravo-Filho, Vasco, Sanft, Debra Meghan, Burnier, Miguel N.
Format: Article
Language:English
Subjects:
Analysis
Antibodies
Cancer therapies
Diagnosis
Health aspects
Liver
Medical prognosis
Melanoma
Metastasis
Patients
Signal transduction
Studies
Uvea
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction. Uveal melanoma (UM) is an intraocular tumor that leads to metastatic disease in approximately 50% of afflicted patients. There is no efficacious treatment for metastatic disease in this cancer. Identification of markers that can offer prognostic and therapeutic value is a major focus in this field at present. KAI1 is a metastasis suppressor gene that has been reported to play a role in various human malignancies, although it has not previously been evaluated in UM. Purpose. To investigate the expression of KAI1 in UM and its potential value as a prognostic marker. Materials and Methods. 18 cases of human primary UM were collected and immunostained for KAI1 expression. A pathologist evaluated staining intensity and distribution semiquantitatively. Each case was categorized as group 1 (low staining) or group 2 (high staining). Results. In group 2, two of the 12 cases presented with metastasis. Conversely, in group 1, five out of 6 cases had metastasis. The mean follow-up of patients who did not develop metastasis was 81.81 months (median: 75 months) versus 42.14 months (median: 44 months) for patients with metastasis. Conclusions. KAI1 is a promising candidate marker that may offer prognostic value in UM; it may also represent a therapeutic target in metastatic disease.
ISSN:2090-004X
2090-0058
DOI:10.1155/2013/683963